EssilorLuxottica 2026 Shareholders Meeting Key Highlights and Insights
- EssilorLuxottica shareholders approved all resolutions proposed by the company’s board of directors during the 2026 Annual Shareholders’ Meeting, held Tuesday in Paris, including a dividend increase and a...
- The board’s proposal to distribute a €4.00 dividend per share for the financial year 2025 received unanimous shareholder support, nearly doubling the payout since 2018.
- Shareholders voted in favor of all 30 resolutions presented during the Ordinary and Extraordinary General Meeting.
EssilorLuxottica shareholders approved all resolutions proposed by the company’s board of directors during the 2026 Annual Shareholders’ Meeting, held Tuesday in Paris, including a dividend increase and a new share-based payment option for investors. The meeting, convened at 3 Mazarium in the French capital, marked a milestone for the global eyewear and vision care leader as it continues to expand its business across vision care, wearables, and med-tech sectors.
Dividend Rises to €4.00 Per Share
The board’s proposal to distribute a €4.00 dividend per share for the financial year 2025 received unanimous shareholder support, nearly doubling the payout since 2018. The dividend will be payable to shareholders of record, with an option for payment in newly issued EssilorLuxottica shares. The board set the issue price for dividend shares at €175.06 per share, reflecting the company’s confidence in its long-term growth trajectory.
All 30 Resolutions Approved
Shareholders voted in favor of all 30 resolutions presented during the Ordinary and Extraordinary General Meeting. These included the adoption of the company’s 2025 financial statements, the reappointment of board members, and the approval of the compensation policy for executive corporate officers. The unanimous support underscored investor confidence in EssilorLuxottica’s strategic direction and governance framework.
Leadership Highlights Strategic Transformation
Following the meeting, Francesco Milleri, Chairman and CEO, and Paul du Saillant, Deputy CEO, issued a joint statement emphasizing the significance of shareholder trust in the company’s ongoing transformation. “The trust expressed by our shareholders at today’s General Meeting reflects a shared belief in the profound transformation we’re delivering,” the executives said. “Our clear and bold strategy, leveraging our expertise across vision care, wearables, and building on our journey in med-tech, is already translating into tangible results, as evidenced by today’s approval of a €4.00 dividend.”
The statement also highlighted the company’s ambition to create lasting value for stakeholders through disciplined execution and innovation. EssilorLuxottica’s expansion into med-tech and wearable technology has positioned it as a leader in integrated vision care solutions, a focus that has resonated with investors amid broader industry shifts.
Share-Based Dividend Option Introduced
In a move to enhance shareholder flexibility, the company introduced an option for investors to receive their dividend payment in the form of newly issued shares. The resolution, approved by shareholders, allows for the conversion of cash dividends into equity at the predetermined price of €175.06 per share. This initiative aligns with EssilorLuxottica’s strategy to strengthen its capital structure while providing shareholders with an opportunity to increase their stake in the company.
Market and Strategic Context
EssilorLuxottica’s 2025 financial performance and the dividend increase reflect the company’s resilience in a competitive global market. The eyewear and vision care industry has seen consolidation and technological innovation, with EssilorLuxottica at the forefront of these trends. The company’s vertical integration—spanning lens manufacturing, frame design, retail distribution, and emerging med-tech applications—has enabled it to capture value across the value chain.
The approval of the compensation policy for executive officers also signals alignment between leadership incentives and long-term shareholder interests. The policy, which includes performance-based metrics, is designed to ensure that executive remuneration reflects the company’s financial health and strategic objectives.
Looking Ahead
With the 2026 Annual Shareholders’ Meeting concluded, EssilorLuxottica is poised to advance its strategic priorities, including further integration of its vision care and wearable technology segments. The company’s focus on innovation, particularly in med-tech, is expected to drive future growth as it seeks to address evolving consumer needs and industry demands.
The dividend payment and share-based option are set to be implemented in the coming weeks, providing shareholders with tangible returns on their investment. As EssilorLuxottica continues to execute its long-term vision, the outcomes of the 2026 meeting serve as a testament to investor confidence in its leadership and strategic direction.
